Femara 2.5 mg (box) 30pcs

Indications: 

• Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
• Extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy.
• First-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer.
• Treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Dosage: The recommended dose is one 2.5 mg tablet administered once a day, regardless to meals. In patients with advanced disease, treatment with Letrozole Tablet should be continued until tumor progression is evident.  Treatment should be discontinued at tumor relapse. No dose adjustment is required for elderly patients. Patients treated with Letrozole Tablet do not require glucocorticoid or mineralocorticoid replacement therapy.

SIde effects: Letrozole is generally well tolerated. The observed adverse reactions are mild or moderate in nature including hot flashes, night sweats, weight increase, nausea, vaginal bleeding & irritation, endometrial proliferation disorders etc.